04.04.19

Oxurion NV Announces Full Enrollment of Its Phase 2 Trial Evaluating Combination of Anti-PlGF (THR-317) and Anti-VEGF (Ranibizumab) for the Treatment of DME

Source: Oxurion NV

03.12.19

Cataract-Surgery Adjuncts Improve Vision in Diabetic Macular Edema

Source: Reuters

03.04.19

Roche/Genentech Study Shows First-Time Proof That AI Can Detect Severity of DME

Source: Genentech

02.08.19

Glycemic Control Tied to Better Outcome of Anti-VEGF Therapy for Diabetic Macular Edema

Source: Reuters

11.13.18

AsclepiX Therapeutics Raises $5 Million to Advance Therapies in AMD and DME

Source: AsclepiX Therapeutics

10.03.18

Fluocinolone Acetonide Implant Effective for Refractory Diabetic Macular Edema

Source: Reuters

09.20.18

Oxurion Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687 for Treatment of DME

Source: Oxurion

09.18.18

Allergan Announces New Partnership With the International Diabetes Federation

Source: Allergan

09.17.18

Oxurion to Present Scientific Findings Supporting Therapeutic Potential of THR-317 and THR-687 at EURETINA

Source: Oxurion NV

05.31.18

Clearside Biomedical Announces Topline Results from Phase 2 Clinical Trial of DME Combination Drug

Source: Clearside Biomedical

View more stories